Vertex Pharmaceuticals
Vertex Pharmaceuticals returns on capital
Annual and trailing 12-month returns on invested capital, equity and assets.
ROIC
% · Annual / TTM
Reported borrowing balances are unavailable in the extracted statements for this period.
ROCE
% · Annual / TTM
ROIIC
% · Annual / TTM
Reported borrowing balances are unavailable in the extracted statements for this period.
ROE
% · Annual / TTM
ROA
% · Annual / TTM
ROIC − WACC
Percentage points · Scenario
Reported borrowing balances are unavailable in the extracted statements for this period.
Quarterly data
| Fiscal period | Ended | ROIC% | ROCE% | ROIIC% | ROE% | ROA% | ROIC − WACCPercentage points |
|---|---|---|---|---|---|---|---|
| FY 2026 Q2 | Jun 30, 2026 | — | 22.02% | — | 23.54% | 17.12% | — |
| FY 2026 Q1 | Mar 31, 2026 | — | 22.45% | — | 24.2% | 17.58% | — |
| FY 2025 Q4 | Dec 31, 2025 | — | 20.48% | — | 22.54% | 16.41% | — |
| FY 2025 Q3 | Sep 30, 2025 | — | 20.66% | — | 22.31% | 15.6% | — |
| FY 2025 Q2 | Jun 30, 2025 | — | 21.51% | — | 22.77% | 16.47% | — |
| FY 2025 Q1 | Mar 31, 2025 | — | -3.79% | — | -5.64% | -4.23% | — |
| FY 2024 Q4 | Dec 31, 2024 | — | -1.22% | — | -3.15% | -2.37% | — |
| FY 2024 Q3 | Sep 30, 2024 | — | -1.49% | — | -2.99% | -2.18% | — |
| FY 2024 Q2 | Jun 30, 2024 | — | -2.08% | — | -3.24% | -2.42% | — |
| FY 2024 Q1 | Mar 31, 2024 | — | 23.25% | — | 24.38% | 18.74% | — |
| FY 2023 Q4 | Dec 31, 2023 | — | 22.16% | — | 22.99% | 17.71% | — |
| FY 2023 Q3 | Sep 30, 2023 | — | 24.06% | — | 23.49% | 18.06% | — |
| FY 2023 Q2 | Jun 30, 2023 | — | 26.42% | — | 24.56% | 18.73% | — |
| FY 2023 Q1 | Mar 31, 2023 | — | 28.87% | — | 25.73% | 19.62% | — |
| FY 2022 Q4 | Dec 31, 2022 | — | 32.27% | — | 27.67% | 21.04% | — |
| FY 2022 Q3 | Sep 30, 2022 | — | 33.48% | — | 29.02% | 22.32% | — |
| FY 2022 Q2 | Jun 30, 2022 | — | 34.85% | — | 30.24% | 22.98% | — |
| FY 2022 Q1 | Mar 31, 2022 | — | 26.39% | — | 24.65% | 18.59% | — |
| FY 2021 Q4 | Dec 31, 2021 | — | 26.29% | — | 24.93% | 18.6% | — |
| FY 2021 Q3 | Sep 30, 2021 | — | 26.5% | — | 24.64% | 18.2% | — |
| FY 2021 Q2 | Jun 30, 2021 | — | 24.12% | — | 23.83% | 17.75% | — |
| FY 2021 Q1 | Mar 31, 2021 | — | 34.51% | — | 35.77% | 26.29% | — |
| FY 2020 Q4 | Dec 31, 2020 | — | 33.89% | — | 36.71% | 27.02% | — |
| FY 2020 Q3 | Sep 30, 2020 | — | 34.52% | — | 40.2% | 28.6% | — |
| FY 2020 Q2 | Jun 30, 2020 | — | 29.44% | — | 33.06% | 24.13% | — |
| FY 2020 Q1 | Mar 31, 2020 | — | 25.66% | — | — | 19.58% | — |
| FY 2019 Q4 | Dec 31, 2019 | — | 19.78% | — | 22.37% | 16.16% | — |
| FY 2019 Q3 | Sep 30, 2019 | — | 15.87% | — | 52.55% | 35.34% | — |
| FY 2019 Q2 | Jun 30, 2019 | — | 19.17% | — | 57.12% | 38.97% | — |
| FY 2019 Q1 | Mar 31, 2019 | — | 18.29% | — | — | 41.07% | — |
| FY 2018 Q4 | Dec 31, 2018 | — | 16.15% | — | 64.87% | 42.83% | — |
| FY 2018 Q3 | Sep 30, 2018 | — | 20.71% | — | 27.54% | 16.55% | — |
| FY 2018 Q2 | Jun 30, 2018 | — | 3.34% | — | 19.06% | 10.9% | — |
| FY 2018 Q1 | Mar 31, 2018 | — | -0.67% | — | 11.58% | 6.55% | — |
| FY 2017 Q4 | Dec 31, 2017 | — | 5.09% | — | 16.53% | 8.18% | — |
| FY 2017 Q3 | Sep 30, 2017 | — | 1.7% | — | 13.89% | 6.74% | — |
| FY 2017 Q2 | Jun 30, 2017 | — | 15.02% | — | 19.56% | 8.91% | — |
| FY 2017 Q1 | Mar 31, 2017 | — | 13.44% | — | 14.4% | 6.53% | — |
| FY 2016 Q4 | Dec 31, 2016 | — | 0.49% | — | -10.69% | -4.15% | — |
| FY 2016 Q3 | Sep 30, 2016 | — | -4.23% | — | -22.51% | -8.67% | — |
| FY 2016 Q2 | Jun 30, 2016 | — | -6.86% | — | -29.32% | -11.17% | — |
| FY 2016 Q1 | Mar 31, 2016 | — | -16.28% | — | -41.31% | -17.16% | — |
| FY 2015 Q4 | Dec 31, 2015 | — | -23.59% | — | -55.22% | -23.02% | — |
| FY 2015 Q3 | Sep 30, 2015 | — | -27.7% | — | -63.45% | -27.24% | — |
| FY 2015 Q2 | Jun 30, 2015 | — | -34.03% | — | -71.03% | -32.69% | — |
| FY 2015 Q1 | Mar 31, 2015 | — | -35.19% | — | -63.85% | -32.3% | — |
| FY 2014 Q4 | Dec 31, 2014 | — | -35.62% | — | -60.68% | -31.74% | — |
| FY 2014 Q3 | Sep 30, 2014 | — | -38.68% | — | -42.76% | -20.75% | — |
| FY 2014 Q2 | Jun 30, 2014 | — | -40.7% | — | -37.81% | -20.06% | — |
| FY 2014 Q1 | Mar 31, 2014 | — | -35.79% | — | -37.38% | -16.1% | — |
| FY 2013 Q4 | Dec 31, 2013 | — | -42.54% | — | -37.78% | -17.53% | — |
| FY 2013 Q3 | Sep 30, 2013 | — | -31.51% | — | -49.33% | -21.33% | — |
| FY 2013 Q2 | Jun 30, 2013 | — | -25.92% | — | -42.27% | -19.23% | — |
| FY 2013 Q1 | Mar 31, 2013 | — | -26.56% | — | -60.44% | -21.39% | — |
| FY 2012 Q4 | Dec 31, 2012 | — | 0.11% | — | -11.99% | -4.31% | — |
| FY 2012 Q3 | Sep 30, 2012 | — | 15.76% | — | 15.78% | 5.31% | — |
| FY 2012 Q2 | Jun 30, 2012 | — | 29.66% | — | 59.96% | 18.61% | — |
| FY 2012 Q1 | Mar 31, 2012 | — | 23.49% | — | — | 15.31% | — |
| FY 2011 Q4 | Dec 31, 2011 | — | 7.43% | — | 4.54% | 1.51% | — |
| FY 2011 Q3 | Sep 30, 2011 | — | -17.74% | — | — | -15.55% | — |
| FY 2011 Q2 | Jun 30, 2011 | — | -52.31% | — | — | -43.28% | — |
| FY 2011 Q1 | Mar 31, 2011 | — | -51.9% | — | — | -46.27% | — |
| FY 2010 Q4 | Dec 31, 2010 | — | — | — | — | — | — |
| FY 2010 Q3 | Sep 30, 2010 | — | — | — | — | — | — |
| FY 2010 Q2 | Jun 30, 2010 | — | — | — | — | — | — |
| FY 2010 Q1 | Mar 31, 2010 | — | — | — | — | — | — |
Sources and calculations
Financial inputs from company filings. Last checked Oct 18, 2026. A dash means missing inputs or an undefined calculation.
Period changes use the preceding fiscal quarter or year. Percentage changes divide by the absolute prior value; a zero or missing baseline has no percentage change. Percentage metrics show changes in percentage points.
Quarterly returns use trailing 12-month earnings and period-end balances averaged with the same fiscal quarter one year earlier. NOPAT uses the reported effective tax rate only when pretax profit is positive and the rate is between 0 and 100%. WACC starts at 7.9%, rounded from the Pharmaceuticals benchmark in NYU Stern · January 2026. It is an editable US sector proxy applied across history, not a company estimate; foreign reporting currencies also need a currency-specific assessment.
Market prices: Yahoo Finance · VRTX, USD. Latest completed close Sep 25, 2026. Price data retrieved Sep 28, 2026.
- ROIC
- NOPAT / average invested capital × 100. NOPAT = operating income × (1 − effective tax rate). Invested capital = equity including noncontrolling interests + debt − cash and equivalents. Average uses period end and one year earlier.
- ROCE
- Operating income / average (assets − current liabilities) × 100, using period end and one year earlier.
- ROIIC
- Year-over-year change in annual/TTM NOPAT / positive year-over-year change in invested capital × 100. Capital reductions and missing inputs yield unavailable values.
- ROE
- Earnings attributable to owners / average equity attributable to owners × 100, using period end and one year earlier.
- ROA
- Net income / average total assets × 100, using period end and one year earlier.
- ROIC − WACC
- ROIC less your WACC assumption, in percentage points. The same scenario rate is applied across history; it is not a reported or historical company WACC.